The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

by | Sep 15, 2025 | Clinical Trials | 0 comments

​ Conditions: Recurrent Cervical Cancer

Interventions: Drug: RC48; Drug: QL1706

Sponsors: Qilu Hospital of Shandong University

Not yet recruiting Conditions: Recurrent Cervical Cancer
Interventions: Drug: RC48; Drug: QL1706
Sponsors: Qilu Hospital of Shandong University
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *